Change in the composition of the Telix Board of Directors

  • Non-executive director Oliver Buck will retire at the annual general meeting
  • Tiffany Olson, Experienced U.S.-Based Pharmaceutical Executive, Named Independent Non-Executive Director

MELBOURNE, Australia and INDIANAPOLIS, March 30, 2022 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, The Company) today announced that Tiffany Olson has been appointed to the Board of Directors, as an Independent Non-Executive Director based in the United States.

Ms. Olson brings extensive experience in commercialization and corporate strategy in oncology, including the radiopharmaceutical industry. Her most recent leadership role was at Cardinal Health, the largest radiopharmaceutical supplier in the United States, where she was President of Cardinal Health Nuclear & Precision Health Solutions, overseeing the company’s radiopharmaceutical manufacturing and nuclear pharmacy network. Cardinal. During her eight-year tenure in this role, she led a major business transformation that resulted in increased market share and profit growth. Prior to her role at Cardinal Health, Ms. Olson served as President of NaviMed and held leadership roles at Eli Lilly and Roche, where she rose to President and CEO of Roche Diagnostics Corporation.

Ms. Olson is currently a member of the board of directors of Castle Biosciences; ERF, Foundation for Education and Research in Nuclear Medicine and Molecular Imaging; and sits on the advisory board of Langham Logistics. Tiffany holds a Bachelor of Commerce degree from the University of Minnesota and an MBA from St. Thomas University in Minnesota. Ms. Olson has received numerous accolades for her work in the health field. She was named one of the “Top 10 Women Leaders of 2020” by Industry Era and was the first woman to receive the Life Science Alley Luminary Award.

Telix Chairman Kevin McCann AO said, “Tiffany is an exceptional addition to our Board of Directors. His appointment supports our governance principles and continues to ensure the board has the right mix of skills, diversity and independence. An accomplished leader with a strong track record of commercializing and building large-scale businesses in the radiopharmaceutical industry, Tiffany’s deep operational understanding of radiopharmaceutical manufacturing, distribution networks and customers will be invaluable as that Telix is ​​deploying its first commercial product. »

Ms. Olson added: “I am delighted to join the Telix Board of Directors at this exciting stage in the company’s journey. I look forward to working with the Telix team to leverage my experience and networks to guide the company through the next phase of its trajectory. , including the launch of Illuccix and the commercialization of follow-on diagnostic and therapeutic products.”

Ms. Olson will join Telix as an independent non-executive director and will be a member of the audit and risk committee. Her appointment takes effect on March 31, 2022. Ms. Olson will stand for re-election as a non-executive director at Telix’s Annual General Meeting, which will be held on May 18, 2022.

Telix informs that Mr. Oliver Buck will step down from the Board of Directors at the company’s 2022 Annual General Meeting. Having served on the Telix Board of Directors since January 16, 2017, Mr. Buck made the decision to step down from the Board of Directors due to the increasing time commitment associated with his portfolio of Board roles. global administration and consultancy.

“On behalf of the Board and the Company, I sincerely thank Oliver for his five years of service with Telix. His technical expertise and industry knowledge were essential during Telix’s early formative years. , and we remain very grateful for his contributions to society.” concluded Kevin McCann.

In accordance with ASX listing rules, an initial notice from the Schedule 3X Director for Ms. Olson accompanies this announcement.

On Telix Pharmaceuticals Limited

Telix is ​​a biopharmaceutical company specializing in the development and marketing of diagnostic and therapeutic products using targeted molecular radiation (MTR). Telix is ​​headquartered in Melbourne, Australia, with international operations in Belgium, Japan, Switzerland and the United States. Telix is ​​developing a portfolio of clinical-stage products that address significant unmet medical needs in oncology and rare diseases. Telix is ​​listed on the Australian Securities Exchange (ASX: TLX). For more information, visit and follow Telix on Twitter (@TelixPharma) and LinkedIn.

Telix flagship product, Illuccix® (kit for the preparation of gallium-68 (68Ga) gozetotide (also called 68Ga PSMA-11) injection) for prostate cancer imaging, has been approved by the United States Food and Drug Administration (FDA),[1] and by the Australian Therapeutic Goods Administration (TGA).[2] Telix is ​​also advancing marketing authorization applications for this experimental candidate in Europe[3] and Canada.[4]

This announcement has been cleared for publication by the Disclosure Committee.

Legal Notice

This announcement may include forward-looking statements relating to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “outlook”, “forecast” and “guidance”, or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed. or implied by these forward-looking statements. research statements. Forward-looking statements are based on the Company’s good faith assumptions about existing financial, market, regulatory and other considerations that affect the Company’s business and operations in the future, and there can be no assurance that the any of the assumptions will turn out to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements regarding: the initiation, timing, progress and results of Telix’s preclinical and clinical studies, and Telix’s research and development of Telix; Telix’s ability to advance product candidates, enroll in and complete clinical studies, including multinational clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialization of Telix’s product candidates, if or when they have been approved; estimates of Telix’s expenses, future revenues and capital needs; the financial performance of Telix; developments relating to Telix’s competitors and industry; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may differ materially from those expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

To the fullest extent permitted by law, Telix disclaims any obligation or undertaking to publicly update or revise any forward-looking statements contained in this announcement, whether as a result of new information, future developments or a change in expectations or assumptions.

The Telix Pharmaceuticals name and logo are trademarks of Telix Pharmaceuticals Limited and its subsidiaries (all rights reserved).

[1] ASX disclosure December 20, 2021.

[2] ASX disclosure November 2, 2021.

[3] ASX disclosure December 10, 2021.

[4] ASX Disclosure December 16, 2020.

Quote View original content to download multimedia:

SOURCE Telix Pharmaceuticals Limited

Company Codes: Australia: TLX

Comments are closed.